


Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β_2 -agonists


Supplementary Material

Supplementary Figure 1. Study design.



ACT, asthma control test; FEV₁, forced expiratory volume in 1 second; HCP, healthcare professional; ICS, inhaled corticosteroids; JSEQ, Jenkin's Sleep Questionnaire; LABA, long-acting β_2 -agonist; US, United States; WPAI, work productivity and activity impairment.

Supplementary Figure 2. Identification of MART prescribing.



*1 patient was missing as they were currently receiving ICS/LABA as reliever only therapy; [†]47 patients were missing as they were currently receiving ICS/LABA as reliever only therapy; [‡]77 patients were missing as they were currently receiving ICS/LABA as reliever only therapy; [§]5 patients were missing as they were currently receiving ICS/LABA as reliever only therapy; ^{||}7 patients were missing as they were currently receiving ICS/LABA as reliever only therapy; ^{**}Includes beclomethasone/formoterol and budesonide/formoterol; ^{††}All ICS/LABA excluding beclomethasone/formoterol and budesonide/formoterol.

FORM, formoterol; ICS, inhaled corticosteroid; LABA, long-acting β_2 -agonist; MART, maintenance and reliever therapy; US, United States.